摘要
目的:探讨阿托伐他汀对急性缺血性脑卒中患者血浆溶血磷脂酸(lysophosphatidic acid,LPA)的干预作用。方法:110例脑梗塞患者,被随机分为阿托伐他汀组(57例)和常规治疗组(53例)。两组均给予钙拮抗剂、脑细胞活化剂、银杏达莫注射液及对症治疗。阿托伐他汀组加用阿托伐他汀20~40mg/d。两组病人入院后第二天清晨空腹静脉采血查血浆LPA和血脂水平,治疗14d后复查。结果:阿托伐他汀组和对照组治疗后LPA较治疗前均显著下降(P<0.05~<0.01),且阿托伐他汀组下降更显著[(2.53±0.75)μmol/L:(1.01±0.56)μmol/L,P<0.01)。两组治疗前后总胆固醇(TC)与低密度脂蛋白-胆固醇(LDL-C)均有显著下降(P<0.01,<0.05),但两组比较无显著性差异(P>0.05)。结论:阿托伐他汀能显著降低急性脑梗塞患者血浆LPA水平,其作用与调脂作用似无明显相关。
Objective: To investigate the effects of atorvastatin on the plasma levels of lysophosphatidic acid in patients with acute cerebral infarction (ACI). Methods: A total of 110 ACI patients were assigned randamly to routine therapy group and atorvastatin group (20-40mg/d, for 14 days above the base of routine therapy). The plasma levels of LPA and blood lipid were determined before and 14 days after treatment. Results: The plasma levels of LPA decreased in both groups after treatment (P〈0. 05-〈0.01), but that in atorvastatin group decreased more significantly (P〈 0.01). The levels of blood lipid in both groups decreased significantly after treatment (P〈0. 05 -〈0. 01), but no difference between two groups (P〈0. 05). Conclusion: Atorvastatin can evidently decrease the plasma levels of LPA in patients with acute cerebral infarction, its effect doesn't depend on the influence of blood lipid.
出处
《心血管康复医学杂志》
CAS
2009年第6期579-581,共3页
Chinese Journal of Cardiovascular Rehabilitation Medicine